Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
Rhea-AI Summary
Aclarion (Nasdaq: ACON) reported that stockholders approved all proposals at the 2026 annual meeting held June 4, 2026. Approvals covered electing seven directors through the 2027 meeting, ratifying Haynie & Company as auditor, and amending the 2022 equity incentive plan.
Aclarion highlighted 196% year-over-year growth in Q1 2026 Nociscan scan volumes, expanded insurance coverage in the United Kingdom, and progress in its United States reimbursement strategy for its AI-driven chronic low back pain assessment technology.
Positive
- All 2026 annual meeting proposals approved by stockholders
- Seven directors elected to serve until the 2027 annual meeting
- Haynie & Company ratified as independent registered public accounting firm
- Amendment to 2022 equity incentive plan approved
- Nociscan scan volumes up 196% year-over-year in Q1 2026
- Expanded insurance coverage for Nociscan in the United Kingdom
Negative
- None.
News Market Reaction – ACON
In the Jun 8 session, ACON declined 5.88%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.9% during that session. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Platform expansion deal | Positive | -0.3% | Agreement with INI to expand Nociscan access and real-world evidence. |
| Jun 01 | Clinical study data | Positive | +2.7% | NIH-funded study highlighting immune-linked subgroups using Nociscan MRS. |
| May 28 | Company response to bid | Positive | +1.0% | Company response to $4.00 per share offer and share repurchase authorization. |
| May 28 | Acquisition proposal | Positive | +1.0% | Echo Lake Capital offer to acquire Aclarion at a stated cash price. |
| May 07 | Trial site expansion | Positive | -3.7% | Addition of first private-practice site to 300-patient CLARITY trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: several positive or strategic updates saw both gains and pullbacks, indicating no consistent pattern of how the stock trades around good news.
Over the last few months, Aclarion reported multiple Nociscan-related developments and strategic events. On May 7, 2026, it expanded the CLARITY trial with a private-practice site, but shares fell. Later in May, an unsolicited acquisition offer at $4.00 per share and a related company response coincided with modest gains. Early June brought clinical and commercial updates, including new evidence partnerships and potential uses beyond surgical planning, with mixed price reactions. Today’s shareholder approval of all annual meeting proposals follows that sequence of operational and strategic milestones.
Key Terms
biomarkers medical
augmented intelligence (ai) algorithms technical
equity incentive plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 4, 2026.
The approved proposals included the election of Jeffrey Thramann, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann, and Amanda Williams to the Board of Directors to serve until the 2027 annual meeting, the ratification of the appointment of Haynie & Company as the Company's independent registered public accounting firm, and the approval of an amendment to the Company's 2022 equity incentive plan.
“On behalf of the Company, I want to thank our stockholders for their continued support of Aclarion,” said Brent Ness, Chief Executive Officer of Aclarion. “We are proud of the progress we are making in 2026, including
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward-Looking Statements
This press release contains information that may constitute forward-looking statements, including with respect to Aclarion’s Board of Directors, Aclarion’s business strategy, and other matters. Forward-looking statements are not guarantees of future performance or results. Forward-looking statements can be identified by the fact that they do not relate strictly to historic or current facts and often use words such as “anticipate,” “estimate,” “expect,” “believe,” “will likely result,” “outlook,” “project” and other words and expressions of similar meaning. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the “Risk Factors” and related discussions in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and Aclarion undertakes no duty to update these statements.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jenna Shinderman
Sodali & Co
Jenna.shinderman@sodali.com
